TATT Stock News 7.90 05/13/2014 14:33:42 Tat Technologies Ltd

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Tat Technologies Ltd (TATT) 7.90 $TATT

11.7% Return Seen to Date on SmarTrend TAT Technologies Call (TATT)
Comtex SmarTrend(R) - Fri May 09, 9:59AM CDT
SmarTrend identified an Uptrend for TAT Technologies (NASDAQ:TATT) on June 24th, 2013 at $7.12. In approximately 11 months, TAT Technologies has returned 11.74% as of today's recent price of $7.95.

Uptrend Call Working As TAT Technologies Stock Rises 12.4% (TATT)
Comtex SmarTrend(R) - Fri May 02, 9:31AM CDT
SmarTrend identified an Uptrend for TAT Technologies (NASDAQ:TATT) on June 24th, 2013 at $7.12. In approximately 10 months, TAT Technologies has returned 12.44% as of today's recent price of $8.00.

TAT Technologies Clarifies Per Share Dividend Amount for Cash Dividend Declared in the Total Amount of $2.0 Million
PR Newswire - Tue Apr 29, 9:04AM CDT
TAT Technologies Ltd. (NASDAQ: TATT), a leading provider of services and products to the commercial and military aerospace and ground defense industries, clarifies that the per share dividend amount for the cash dividend declared on March 19, 2014, in the total amount of $2.0 million (approximately NIS6.97 million), is $0.22713758 per share (or approximately $0.23 and NIS0.79 per share as previously reported), for all of the shareholders of TAT Technologies of record on April 23, 2014. Such cash dividend will be paid by TAT Technologies on May 7, 2014. Tax will be withheld with respect to payments made to individuals and non-Israeli residents at a rate of 20%.

TAT Technologies Shares Up 13.1% Since SmarTrend's Buy Recommendation (TATT)
Comtex SmarTrend(R) - Thu Apr 24, 4:58PM CDT
SmarTrend identified an Uptrend for TAT Technologies (NASDAQ:TATT) on June 24th, 2013 at $7.12. In approximately 10 months, TAT Technologies has returned 13.14% as of today's recent price of $8.05.

TAT Technologies Has Returned 18.6% Since SmarTrend Recommendation (TATT)
Comtex SmarTrend(R) - Thu Apr 17, 11:13AM CDT
SmarTrend identified an Uptrend for TAT Technologies (NASDAQ:TATT) on June 24th, 2013 at $7.12. In approximately 10 months, TAT Technologies has returned 18.62% as of today's recent price of $8.44.

Shares of TATT Up 17.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Apr 03, 9:20AM CDT
SmarTrend identified an Uptrend for TAT Technologies (NASDAQ:TATT) on June 24th, 2013 at $7.12. In approximately 9 months, TAT Technologies has returned 17.86% as of today's recent price of $8.39.

TAT Technologies Announces Closing of the Transaction to Sell Controlling Interest In Bental Industries Ltd. to Bental Investments Agshah Ltd.
PR Newswire - Thu Mar 27, 8:40AM CDT
ï"

TAT Technologies Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
PR Newswire - Fri Mar 21, 1:15PM CDT
ï"

TAT Technologies announces dividend of USD0.23 per share
M2 - Fri Mar 21, 6:25AM CDT
The board of directors of TAT Technologies Ltd (NASDAQ: TATT), a provider of aerospace and ground defence services and products, approved a cash dividend in the total amount of USD2.0m or about USD0.23 per share at its meeting on 19 March 2014, the company disclosed on Thursday.

TAT Technologies Declares a $2.0 Million Cash Dividend and Approves a Grant of 195,000 Options to its Senior Executives
PR Newswire - Thu Mar 20, 4:50PM CDT
ï"

Nasdaq stocks posting largest volume decreases
AP - Wed Mar 12, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume decliners on Nasdaq at the close of trading:

TAT Technologies Announces Execution of an Agreement to Sell a Controlling Interest in Bental Industries Ltd. to Bental Investments Agshah Ltd.
PR Newswire - Tue Feb 18, 5:00AM CST
ï"
Scroll down for more posts ▼

Top 10 Most Recent News Articles

WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 188

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine

Updated Category News Views 384

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 260

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 267

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 392

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 382

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 371

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading
El Pollo Loco Faces Class Action Over Wage Practices

Updated Category News Views 472

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 344

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 433

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
/news?page=2">More News Articles